C

Cellectis SA
D

CLLS

1.52000
USD
-0.02
(-1.30%)
مغلق
حجم التداول
136
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
152,142,687
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALLO
    -0.07500
    (-3.33%)
    2.17500 USD
    B
    BEAM
    -2.705
    (-8.16%)
    30.445 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Cellectis SA

القطاع: Healthcare
الصناعة: Biotechnology
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.